UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

The Lancet (British edition), 2011-08, Vol.378 (9792), p.667-675

2011

Volltextzugriff (PDF)

Challenges in accelerated approvals for gene therapies

Molecular therapy, 2023-09, Vol.31 (9), p.2572-2574

2023

Volltextzugriff (PDF)

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Gastro hep advances, 2024, Vol.3 (1), p.9-16

2024

Volltextzugriff (PDF)

The need for ethical and pragmatic strategies for sample and data collection during public health emergencies-minimizing missed opportunities

European heart journal, 2021-09, Vol.42 (33), p.3114-3116

2021

Volltextzugriff (PDF)

Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina

JACC. Heart failure, 2015, Vol.3 (1), p.22-29

2015

Volltextzugriff (PDF)

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Anti-cancer drugs, 2012-03, Vol.23 (3), p.335-341

2012

Volltextzugriff (PDF)

The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study

Leukemia & lymphoma, 2015-01, Vol.56 (9), p.2585-2591

2015

Volltextzugriff (PDF)

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

Cephalalgia, 2014-10, Vol.34 (12), p.968-976

2014

Volltextzugriff (PDF)

A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study

Journal of hepatology, 2023-06, Vol.78, p.S822-S823

2023

Volltextzugriff (PDF)

FRI-515 - A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study

Journal of hepatology, 2023-06, Vol.78, p.S822-S823

2023

Volltextzugriff (PDF)

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

Cephalalgia, 2014-06, Vol.34 (7), p.483-492

2014

Volltextzugriff (PDF)

The IV Pharmaokinetics of Single and Multiple Doses of LBR-101 in Healthy Volunteers (P7.189)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials

Pharmaceutical medicine, 2023, Vol.37 (1), p.17-24

2023

Volltextzugriff (PDF)

Fetal Therapies and Clinical Research: Beyond Risk and Benefit

American journal of bioethics, 2022-03, Vol.22 (3), p.1-3

2022

Volltextzugriff (PDF)

Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

mAbs, 2014-07, Vol.6 (4), p.871-878

2014

Volltextzugriff (PDF)

Safety and Tolerability of LBR-101, a Humanized Monoclonal Antibody That Blocks the Binding of CGRP to Its Receptor - Results of the Phase 1 Program (P7.190)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Cardiovascular and Hemodynamic Parameters in Women Following IV Administration of LBR-101, a Monoclonal Antibody Against CGRP (P7.198)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Oral Bioavailability of the Selective Cardiac Myosin Activator CK-1827452: Chronic Oral Inotropic Therapy for Heart Failure?

Journal of cardiac failure, 2007, Vol.13 (6), p.S148-S148

2007

Volltextzugriff (PDF)

Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease

Journal of neuromuscular diseases, 2024-01, Vol.11 (2), p.499-523

2024

Volltextzugriff (PDF)

Globalization of Clinical Research and Assessment of Global Access to Treatments Approved between 2006–2015

Escandon, Rafael Duncan

2019

Volltextzugriff (PDF)

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma

Leukemia & lymphoma, 2015-10, Vol.56 (10), p.2945-2952

2015

Volltextzugriff (PDF)

Design of a Phase 1/2 Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy in Adults With Classic Congenital Adrenal Hyperplasia (CAH) Due to 21-hydroxylase Deficiency Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A82-A82

2021

Volltextzugriff (PDF)

The Novel Kinesin Spindle Protein Inhibitor SB-743921 Exhibits Marked Activity In In Vivo and In Vitro In Models of Aggressive Diffuse Large B-Cell Lymphoma

Blood, 2010-11, Vol.116 (21), p.118-118

2010

Volltextzugriff (PDF)

Colesterol total y discapacidad en ancianos hospitalizados: más allá de la enfermedad cardiovascular

Revista colombiana de cardiología (Bogotá, Colombia : 1989), 2018-01, Vol.25 (1), p.33-42

2018

Volltextzugriff (PDF)

Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina

Journal of cardiac failure, 2009, Vol.15 (6), p.S67-S67

2009

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

Challenges in accelerated approvals for gene therapies

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

The need for ethical and pragmatic strategies for sample and data collection during public health emergencies-minimizing missed opportunities

Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study

FRI-515 - A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

The IV Pharmaokinetics of Single and Multiple Doses of LBR-101 in Healthy Volunteers (P7.189)

Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials

Fetal Therapies and Clinical Research: Beyond Risk and Benefit

Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide

Safety and Tolerability of LBR-101, a Humanized Monoclonal Antibody That Blocks the Binding of CGRP to Its Receptor - Results of the Phase 1 Program (P7.190)

Cardiovascular and Hemodynamic Parameters in Women Following IV Administration of LBR-101, a Monoclonal Antibody Against CGRP (P7.198)

Oral Bioavailability of the Selective Cardiac Myosin Activator CK-1827452: Chronic Oral Inotropic Therapy for Heart Failure?

Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease

Globalization of Clinical Research and Assessment of Global Access to Treatments Approved between 2006–2015

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma

The Novel Kinesin Spindle Protein Inhibitor SB-743921 Exhibits Marked Activity In In Vivo and In Vitro In Models of Aggressive Diffuse Large B-Cell Lymphoma

Colesterol total y discapacidad en ancianos hospitalizados: más allá de la enfermedad cardiovascular

Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina

Suchergebnisse filtern